Mon panier

Human NKG2A / CD159a Protein, His Tag

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
NKA-H5244-100ug
$395.00
NKA-H5244-1mg (500ug X 2)
$2615.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Synonyms

    NKG2A, CD159a, KLRC1, NK cell receptor A

  • Source

    Human NKG2A, His Tag (NKA-H5244) is expressed from human 293 cells (HEK293). It contains AA Pro 94 - Leu 233 (Accession # P26715-1).

    Predicted N-terminus: His

    Request for sequence
  • Molecular Characterization

    NKG2A Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the N-terminus.

    The protein has a calculated MW of 17.9 kDa. The protein migrates as 30-40 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • Purity

    >90% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Shipping and Storage

    This product is shipped at ambient temperature.

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • SDS-PAGE

    NKG2A SDS-PAGE

    Human NKG2A, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

Avis des utilisateurs
Publier un commentaire

  • A***n2024-09-17
    J'aime
    I used this recombinant protein to test function of a gRV transduction on iPS-derived cells. The product went into solution quickly during reconstitution and provided expected results from positive controls and testing samples. Signal was clear on a flow cytometry based readout using Streptavidin-Brilliant Violet 711. I used this at 5 ug at a concentration of 100 ug/mL on 50,000 total cells. No support was needed, as the provided data sheet and CoA are thorough and easy to follow. Very satisfied with my experience.

Introduction de fond

NKG2A/CD159a is a transmembrane protein belonging to the CD94/NKG2 family of C-type lectin-like receptors that inhibits innate immune system activation, also known as KLRC1, CD159a, NK cell receptor A and NKG2-A/NKG2-B type II integral membrane protein. NKG2A marks a unique immune effector subset preferentially co-expressing the tissue-resident CD103 molecule, but not immune checkpoint inhibitors. NKG2A blockade therapy operated through CD8 T cells, but not NK cells. The increase in NKG2A expression might be induced by IL-10, which was present at a high level in the plasma of HCC patients. Blocking IL-10 could specifically inhibit NKG2A expression in NK cells. These findings indicate that NKG2A expression is influenced by factors from cancer nests and contributes to NK cell exhaustion, suggesting that NKG2A blockade has the potential to restore immunity against liver tumors by reversing NK cell exhaustion.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    NK cell lectin-like receptor subfamily C member 1

  • Catégorie:

  • Nombre de médicaments répertoriés:

    0 Détails

  • Nombre de médicaments cliniques:

    6 Détails

  • Étape de développement la plus élevée:

    Phase 3 Clinical

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte